High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus

Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk T. High frequency and allele‐specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Breast cancer and ovarian cancer are common malignancies in Belarus accounting for about 350...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical genetics 2010-10, Vol.78 (4), p.364-372
Hauptverfasser: Bogdanova, NV, Antonenkova, NN, Rogov, YI, Karstens, JH, Hillemanns, P, Dörk, T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 372
container_issue 4
container_start_page 364
container_title Clinical genetics
container_volume 78
creator Bogdanova, NV
Antonenkova, NN
Rogov, YI
Karstens, JH
Hillemanns, P
Dörk, T
description Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk T. High frequency and allele‐specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Breast cancer and ovarian cancer are common malignancies in Belarus accounting for about 3500 and 800 new cases per year, respectively. For breast cancer, the rates and age of onset appear to vary significantly in regions differentially affected by the Chernobyl accident. We assessed the frequency and distribution of three BRCA1 founder mutations 5382insC, 4153delA and Cys61Gly in two hospital‐based series of 1945 unselected breast cancer patients and of 201 unselected ovarian cancer patients from Belarus as well as in 1019 healthy control females from the same population. Any of these mutations were identified in 4.4% of the breast cancer patients, 26.4% of the ovarian cancer patients and 0.5% of the controls. In the breast cancer patients, BRCA1 mutations were strongly associated with earlier age at diagnosis, with oestrogen receptor (ER) negative tumours and with a first‐degree family history of breast cancer, although only 35% of the identified BRCA1 mutation carriers had such a family history. There were no marked differences in the regional distribution of BRCA1 mutations, so that the significant differences in age at diagnosis and family history of breast cancer patients from areas afflicted by the Chernobyl accident could not be explained by BRCA1. We next observed a higher impact and a shifted mutational spectrum of BRCA1 in the series of Byelorussian ovarian cancer patients where the three founder mutations accounted for 26.4% (53/201). While the Cys61Gly mutation appeared underrepresented in ovarian cancer as compared with breast cancer cases from the same population (p = 0.01), the 4153delA mutation made a higher contribution to ovarian cancer than to breast cancer (p < 0.01). BRCA1 mutations were significantly enriched among ovarian cancer cases with a first‐degree family history of breast or ovarian cancer, whereas the median age at ovarian cancer diagnosis was not different between mutation carriers and non‐carriers. Taken together, these results identify three BRCA1 founder mutations as key components of inherited breast and ovarian cancer susceptibility in Belarus and might have implications for cancer prevention, treatment and genetic counselling in this population.
doi_str_mv 10.1111/j.1399-0004.2010.01473.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_847436927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>762686160</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4953-ee4770fe1b9d6ea5a3291c67314971e00a16c3bbeb7df856b137194ff7c4cc483</originalsourceid><addsrcrecordid>eNqNkU2PFCEQhonRuOPqXzDExHjqERoamoOH3c7OrMlmTYwfR0LThTL2xwjdOnP2j0vvzI6JF-VSQD1vQdWLEKZkSdN6vVlSplRGCOHLnKRbQrlky90DtDglHqJFCipTVLAz9CTGTToyWajH6CwnhVB5IRbo17X_8hW7AN8n6O0em77Bpm2hhSxuwXrnLW68cxBSGiIeHL58X11Q7IapbyDgbhrN6Ic-Yt_jOoCJI7YmseGu1vDDBG_6-6ttYqEfY3px6PAltCZM8Sl65Ewb4dkxnqOPq6sP1XV28279trq4ySxXBcsAuJTEAa1VI8AUhuWKWiEZ5UpSIMRQYVldQy0bVxaipkxSxZ2TllvLS3aOXh3qbsOQ2o2j7ny00Lamh2GKuuSSszQX-U9SilyUggqSyBd_kZthCn1qQ8v5W1wxlqDyANkwxBjA6W3wnQl7TYmeDdUbPfumZ9_0bKi-M1TvkvT5sf5Ud9CchPcOJuDlETDRmtaFNGgf_3CMKsXKmXtz4H76Fvb__QFdra_mXdJnB72PI-xOehO-6WSBLPTn27VeVZ9WtKxudcF-A30ayq4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>749714933</pqid></control><display><type>article</type><title>High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Bogdanova, NV ; Antonenkova, NN ; Rogov, YI ; Karstens, JH ; Hillemanns, P ; Dörk, T</creator><creatorcontrib>Bogdanova, NV ; Antonenkova, NN ; Rogov, YI ; Karstens, JH ; Hillemanns, P ; Dörk, T</creatorcontrib><description>Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk T. High frequency and allele‐specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Breast cancer and ovarian cancer are common malignancies in Belarus accounting for about 3500 and 800 new cases per year, respectively. For breast cancer, the rates and age of onset appear to vary significantly in regions differentially affected by the Chernobyl accident. We assessed the frequency and distribution of three BRCA1 founder mutations 5382insC, 4153delA and Cys61Gly in two hospital‐based series of 1945 unselected breast cancer patients and of 201 unselected ovarian cancer patients from Belarus as well as in 1019 healthy control females from the same population. Any of these mutations were identified in 4.4% of the breast cancer patients, 26.4% of the ovarian cancer patients and 0.5% of the controls. In the breast cancer patients, BRCA1 mutations were strongly associated with earlier age at diagnosis, with oestrogen receptor (ER) negative tumours and with a first‐degree family history of breast cancer, although only 35% of the identified BRCA1 mutation carriers had such a family history. There were no marked differences in the regional distribution of BRCA1 mutations, so that the significant differences in age at diagnosis and family history of breast cancer patients from areas afflicted by the Chernobyl accident could not be explained by BRCA1. We next observed a higher impact and a shifted mutational spectrum of BRCA1 in the series of Byelorussian ovarian cancer patients where the three founder mutations accounted for 26.4% (53/201). While the Cys61Gly mutation appeared underrepresented in ovarian cancer as compared with breast cancer cases from the same population (p = 0.01), the 4153delA mutation made a higher contribution to ovarian cancer than to breast cancer (p &lt; 0.01). BRCA1 mutations were significantly enriched among ovarian cancer cases with a first‐degree family history of breast or ovarian cancer, whereas the median age at ovarian cancer diagnosis was not different between mutation carriers and non‐carriers. Taken together, these results identify three BRCA1 founder mutations as key components of inherited breast and ovarian cancer susceptibility in Belarus and might have implications for cancer prevention, treatment and genetic counselling in this population.</description><identifier>ISSN: 0009-9163</identifier><identifier>EISSN: 1399-0004</identifier><identifier>DOI: 10.1111/j.1399-0004.2010.01473.x</identifier><identifier>PMID: 20569256</identifier><identifier>CODEN: CLGNAY</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Age ; Age of Onset ; Alleles ; Biological and medical sciences ; BRCA1 ; BRCA1 protein ; Breast cancer ; Breast Neoplasms - epidemiology ; Breast Neoplasms - genetics ; Chernobyl Nuclear Accident ; DNA Mutational Analysis ; Environmental Exposure ; Estrogen receptors ; Female ; Founder Effect ; founder mutations ; Fundamental and applied biological sciences. Psychology ; Gene Frequency ; General aspects. Genetic counseling ; Genes, BRCA1 ; Genetic Association Studies ; Genetic disorders ; Genetic Predisposition to Disease ; genetic susceptibility ; Genetic Testing ; Genetics of eukaryotes. Biological and molecular evolution ; Human ; Humans ; Karsten ; Malignancy ; Medical genetics ; Medical sciences ; Molecular and cellular biology ; Mutation ; Ovarian cancer ; Ovarian Neoplasms - epidemiology ; Ovarian Neoplasms - genetics ; Population genetics ; Population genetics, reproduction patterns ; radiation ; Republic of Belarus - epidemiology</subject><ispartof>Clinical genetics, 2010-10, Vol.78 (4), p.364-372</ispartof><rights>2010 John Wiley &amp; Sons A/S</rights><rights>2015 INIST-CNRS</rights><rights>2010 John Wiley &amp; Sons A/S.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4953-ee4770fe1b9d6ea5a3291c67314971e00a16c3bbeb7df856b137194ff7c4cc483</citedby><cites>FETCH-LOGICAL-c4953-ee4770fe1b9d6ea5a3291c67314971e00a16c3bbeb7df856b137194ff7c4cc483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1399-0004.2010.01473.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1399-0004.2010.01473.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23199386$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20569256$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bogdanova, NV</creatorcontrib><creatorcontrib>Antonenkova, NN</creatorcontrib><creatorcontrib>Rogov, YI</creatorcontrib><creatorcontrib>Karstens, JH</creatorcontrib><creatorcontrib>Hillemanns, P</creatorcontrib><creatorcontrib>Dörk, T</creatorcontrib><title>High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus</title><title>Clinical genetics</title><addtitle>Clin Genet</addtitle><description>Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk T. High frequency and allele‐specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Breast cancer and ovarian cancer are common malignancies in Belarus accounting for about 3500 and 800 new cases per year, respectively. For breast cancer, the rates and age of onset appear to vary significantly in regions differentially affected by the Chernobyl accident. We assessed the frequency and distribution of three BRCA1 founder mutations 5382insC, 4153delA and Cys61Gly in two hospital‐based series of 1945 unselected breast cancer patients and of 201 unselected ovarian cancer patients from Belarus as well as in 1019 healthy control females from the same population. Any of these mutations were identified in 4.4% of the breast cancer patients, 26.4% of the ovarian cancer patients and 0.5% of the controls. In the breast cancer patients, BRCA1 mutations were strongly associated with earlier age at diagnosis, with oestrogen receptor (ER) negative tumours and with a first‐degree family history of breast cancer, although only 35% of the identified BRCA1 mutation carriers had such a family history. There were no marked differences in the regional distribution of BRCA1 mutations, so that the significant differences in age at diagnosis and family history of breast cancer patients from areas afflicted by the Chernobyl accident could not be explained by BRCA1. We next observed a higher impact and a shifted mutational spectrum of BRCA1 in the series of Byelorussian ovarian cancer patients where the three founder mutations accounted for 26.4% (53/201). While the Cys61Gly mutation appeared underrepresented in ovarian cancer as compared with breast cancer cases from the same population (p = 0.01), the 4153delA mutation made a higher contribution to ovarian cancer than to breast cancer (p &lt; 0.01). BRCA1 mutations were significantly enriched among ovarian cancer cases with a first‐degree family history of breast or ovarian cancer, whereas the median age at ovarian cancer diagnosis was not different between mutation carriers and non‐carriers. Taken together, these results identify three BRCA1 founder mutations as key components of inherited breast and ovarian cancer susceptibility in Belarus and might have implications for cancer prevention, treatment and genetic counselling in this population.</description><subject>Age</subject><subject>Age of Onset</subject><subject>Alleles</subject><subject>Biological and medical sciences</subject><subject>BRCA1</subject><subject>BRCA1 protein</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - genetics</subject><subject>Chernobyl Nuclear Accident</subject><subject>DNA Mutational Analysis</subject><subject>Environmental Exposure</subject><subject>Estrogen receptors</subject><subject>Female</subject><subject>Founder Effect</subject><subject>founder mutations</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gene Frequency</subject><subject>General aspects. Genetic counseling</subject><subject>Genes, BRCA1</subject><subject>Genetic Association Studies</subject><subject>Genetic disorders</subject><subject>Genetic Predisposition to Disease</subject><subject>genetic susceptibility</subject><subject>Genetic Testing</subject><subject>Genetics of eukaryotes. Biological and molecular evolution</subject><subject>Human</subject><subject>Humans</subject><subject>Karsten</subject><subject>Malignancy</subject><subject>Medical genetics</subject><subject>Medical sciences</subject><subject>Molecular and cellular biology</subject><subject>Mutation</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - epidemiology</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Population genetics</subject><subject>Population genetics, reproduction patterns</subject><subject>radiation</subject><subject>Republic of Belarus - epidemiology</subject><issn>0009-9163</issn><issn>1399-0004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU2PFCEQhonRuOPqXzDExHjqERoamoOH3c7OrMlmTYwfR0LThTL2xwjdOnP2j0vvzI6JF-VSQD1vQdWLEKZkSdN6vVlSplRGCOHLnKRbQrlky90DtDglHqJFCipTVLAz9CTGTToyWajH6CwnhVB5IRbo17X_8hW7AN8n6O0em77Bpm2hhSxuwXrnLW68cxBSGiIeHL58X11Q7IapbyDgbhrN6Ic-Yt_jOoCJI7YmseGu1vDDBG_6-6ttYqEfY3px6PAltCZM8Sl65Ewb4dkxnqOPq6sP1XV28279trq4ySxXBcsAuJTEAa1VI8AUhuWKWiEZ5UpSIMRQYVldQy0bVxaipkxSxZ2TllvLS3aOXh3qbsOQ2o2j7ny00Lamh2GKuuSSszQX-U9SilyUggqSyBd_kZthCn1qQ8v5W1wxlqDyANkwxBjA6W3wnQl7TYmeDdUbPfumZ9_0bKi-M1TvkvT5sf5Ud9CchPcOJuDlETDRmtaFNGgf_3CMKsXKmXtz4H76Fvb__QFdra_mXdJnB72PI-xOehO-6WSBLPTn27VeVZ9WtKxudcF-A30ayq4</recordid><startdate>201010</startdate><enddate>201010</enddate><creator>Bogdanova, NV</creator><creator>Antonenkova, NN</creator><creator>Rogov, YI</creator><creator>Karstens, JH</creator><creator>Hillemanns, P</creator><creator>Dörk, T</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201010</creationdate><title>High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus</title><author>Bogdanova, NV ; Antonenkova, NN ; Rogov, YI ; Karstens, JH ; Hillemanns, P ; Dörk, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4953-ee4770fe1b9d6ea5a3291c67314971e00a16c3bbeb7df856b137194ff7c4cc483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Age</topic><topic>Age of Onset</topic><topic>Alleles</topic><topic>Biological and medical sciences</topic><topic>BRCA1</topic><topic>BRCA1 protein</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - genetics</topic><topic>Chernobyl Nuclear Accident</topic><topic>DNA Mutational Analysis</topic><topic>Environmental Exposure</topic><topic>Estrogen receptors</topic><topic>Female</topic><topic>Founder Effect</topic><topic>founder mutations</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gene Frequency</topic><topic>General aspects. Genetic counseling</topic><topic>Genes, BRCA1</topic><topic>Genetic Association Studies</topic><topic>Genetic disorders</topic><topic>Genetic Predisposition to Disease</topic><topic>genetic susceptibility</topic><topic>Genetic Testing</topic><topic>Genetics of eukaryotes. Biological and molecular evolution</topic><topic>Human</topic><topic>Humans</topic><topic>Karsten</topic><topic>Malignancy</topic><topic>Medical genetics</topic><topic>Medical sciences</topic><topic>Molecular and cellular biology</topic><topic>Mutation</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - epidemiology</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Population genetics</topic><topic>Population genetics, reproduction patterns</topic><topic>radiation</topic><topic>Republic of Belarus - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bogdanova, NV</creatorcontrib><creatorcontrib>Antonenkova, NN</creatorcontrib><creatorcontrib>Rogov, YI</creatorcontrib><creatorcontrib>Karstens, JH</creatorcontrib><creatorcontrib>Hillemanns, P</creatorcontrib><creatorcontrib>Dörk, T</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bogdanova, NV</au><au>Antonenkova, NN</au><au>Rogov, YI</au><au>Karstens, JH</au><au>Hillemanns, P</au><au>Dörk, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus</atitle><jtitle>Clinical genetics</jtitle><addtitle>Clin Genet</addtitle><date>2010-10</date><risdate>2010</risdate><volume>78</volume><issue>4</issue><spage>364</spage><epage>372</epage><pages>364-372</pages><issn>0009-9163</issn><eissn>1399-0004</eissn><coden>CLGNAY</coden><abstract>Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk T. High frequency and allele‐specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Breast cancer and ovarian cancer are common malignancies in Belarus accounting for about 3500 and 800 new cases per year, respectively. For breast cancer, the rates and age of onset appear to vary significantly in regions differentially affected by the Chernobyl accident. We assessed the frequency and distribution of three BRCA1 founder mutations 5382insC, 4153delA and Cys61Gly in two hospital‐based series of 1945 unselected breast cancer patients and of 201 unselected ovarian cancer patients from Belarus as well as in 1019 healthy control females from the same population. Any of these mutations were identified in 4.4% of the breast cancer patients, 26.4% of the ovarian cancer patients and 0.5% of the controls. In the breast cancer patients, BRCA1 mutations were strongly associated with earlier age at diagnosis, with oestrogen receptor (ER) negative tumours and with a first‐degree family history of breast cancer, although only 35% of the identified BRCA1 mutation carriers had such a family history. There were no marked differences in the regional distribution of BRCA1 mutations, so that the significant differences in age at diagnosis and family history of breast cancer patients from areas afflicted by the Chernobyl accident could not be explained by BRCA1. We next observed a higher impact and a shifted mutational spectrum of BRCA1 in the series of Byelorussian ovarian cancer patients where the three founder mutations accounted for 26.4% (53/201). While the Cys61Gly mutation appeared underrepresented in ovarian cancer as compared with breast cancer cases from the same population (p = 0.01), the 4153delA mutation made a higher contribution to ovarian cancer than to breast cancer (p &lt; 0.01). BRCA1 mutations were significantly enriched among ovarian cancer cases with a first‐degree family history of breast or ovarian cancer, whereas the median age at ovarian cancer diagnosis was not different between mutation carriers and non‐carriers. Taken together, these results identify three BRCA1 founder mutations as key components of inherited breast and ovarian cancer susceptibility in Belarus and might have implications for cancer prevention, treatment and genetic counselling in this population.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20569256</pmid><doi>10.1111/j.1399-0004.2010.01473.x</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-9163
ispartof Clinical genetics, 2010-10, Vol.78 (4), p.364-372
issn 0009-9163
1399-0004
language eng
recordid cdi_proquest_miscellaneous_847436927
source MEDLINE; Access via Wiley Online Library
subjects Age
Age of Onset
Alleles
Biological and medical sciences
BRCA1
BRCA1 protein
Breast cancer
Breast Neoplasms - epidemiology
Breast Neoplasms - genetics
Chernobyl Nuclear Accident
DNA Mutational Analysis
Environmental Exposure
Estrogen receptors
Female
Founder Effect
founder mutations
Fundamental and applied biological sciences. Psychology
Gene Frequency
General aspects. Genetic counseling
Genes, BRCA1
Genetic Association Studies
Genetic disorders
Genetic Predisposition to Disease
genetic susceptibility
Genetic Testing
Genetics of eukaryotes. Biological and molecular evolution
Human
Humans
Karsten
Malignancy
Medical genetics
Medical sciences
Molecular and cellular biology
Mutation
Ovarian cancer
Ovarian Neoplasms - epidemiology
Ovarian Neoplasms - genetics
Population genetics
Population genetics, reproduction patterns
radiation
Republic of Belarus - epidemiology
title High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T07%3A43%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20frequency%20and%20allele-specific%20differences%20of%20BRCA1%20founder%20mutations%20in%20breast%20cancer%20and%20ovarian%20cancer%20patients%20from%20Belarus&rft.jtitle=Clinical%20genetics&rft.au=Bogdanova,%20NV&rft.date=2010-10&rft.volume=78&rft.issue=4&rft.spage=364&rft.epage=372&rft.pages=364-372&rft.issn=0009-9163&rft.eissn=1399-0004&rft.coden=CLGNAY&rft_id=info:doi/10.1111/j.1399-0004.2010.01473.x&rft_dat=%3Cproquest_cross%3E762686160%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=749714933&rft_id=info:pmid/20569256&rfr_iscdi=true